Literature DB >> 23730140

Treatment of Late Class II Antibody-Mediated Rejection Status Postkidney Transplantation: Two Case Reports.

Eric Siskind1, Madhu Bhaskaran, Fouad Boctor, Kavin Shah, Ernesto Molmenti.   

Abstract

We are describing the successful treatment of two cases of late Class II antibody mediated rejection status postkidney transplantation. The first patient was treated with a combination of plasmapheresis, intravenous immunoglobulin (IVIG), and stenting of the transplanted renal artery. The second was treated with IVIG and pulse steroids.

Entities:  

Keywords:  angioplasty; artery; immune system; kidney; renal disease; stent; transplant

Year:  2012        PMID： 23730140      PMCID： PMC3444007          DOI： 10.1055/s-0032-1315622

Source DB:  PubMed          Journal:  Int J Angiol        ISSN： 1061-1711


  10 in total

1.  Treatment of acute antibody-mediated rejection: a single-center experience.

Authors:  M Rodríguez Ferrero; A Rincón; L Bucalo; A Rementería; F Anaya
Journal:  Transplant Proc       Date:  2010-10       Impact factor: 1.066

2.  Treatment of antibody-mediated rejection after kidney transplantation.

Authors:  K K Sureshkumar; I U Oti; S C Baroody; S M Hussain; B J Carpenter; D D Nghiem; R J Marcus
Journal:  Transplant Proc       Date:  2008-06       Impact factor: 1.066

Review 3.  Accelerated arteriosclerosis: a form of transplant arteriopathy.

Authors:  Gary S Hill; Dominique Nochy; Alexandre Loupy
Journal:  Curr Opin Organ Transplant       Date:  2010-02       Impact factor: 2.640

Review 4.  Antibody-mediated rejection in kidney transplantation: an update.

Authors:  Jessica G Lucas; Jeannie P Co; Uzoamaka T Nwaogwugwu; Imran Dosani; Kalathil K Sureshkumar
Journal:  Expert Opin Pharmacother       Date:  2011-02-05       Impact factor: 3.889

5.  Late acute kidney transplant rejection: clinicopathological correlates and response to corticosteroid therapy.

Authors:  R Nair; N Agrawal; M Lebaeau; S Tuteja; P K G Chandran; M Suneja
Journal:  Transplant Proc       Date:  2009-12       Impact factor: 1.066

6.  National conference to assess antibody-mediated rejection in solid organ transplantation.

Authors:  Steven K Takemoto; Adriana Zeevi; Sandy Feng; Robert B Colvin; Stanley Jordan; Jon Kobashigawa; Jerzy Kupiec-Weglinski; Arthur Matas; Robert A Montgomery; Peter Nickerson; Jeffrey L Platt; Hamid Rabb; Richard Thistlethwaite; Dolly Tyan; Francis L Delmonico
Journal:  Am J Transplant       Date:  2004-07       Impact factor: 8.086

7.  Comparison of combination Plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection.

Authors:  C Lefaucheur; D Nochy; J Andrade; J Verine; C Gautreau; D Charron; G S Hill; D Glotz; C Suberbielle-Boissel
Journal:  Am J Transplant       Date:  2009-05       Impact factor: 8.086

8.  The utility of splenectomy as rescue treatment for severe acute antibody mediated rejection.

Authors:  J E Locke; A A Zachary; M Haas; J K Melancon; D S Warren; C E Simpkins; D L Segev; R A Montgomery
Journal:  Am J Transplant       Date:  2007-04       Impact factor: 8.086

9.  Plasmapheresis and intravenous immunoglobulin in early antibody-mediated rejection of the renal allograft: a single-center experience.

Authors:  Janka Slatinska; Eva Honsova; Marcela Burgelova; Antonij Slavcev; Ondrej Viklicky
Journal:  Ther Apher Dial       Date:  2009-04       Impact factor: 1.762

10.  Impact of rituximab therapy for treatment of acute humoral rejection.

Authors:  Z Kaposztas; H Podder; S Mauiyyedi; O Illoh; R Kerman; M Reyes; V Pollard; B D Kahan
Journal:  Clin Transplant       Date:  2009 Jan-Feb       Impact factor: 2.863
  10 in total
  2 in total

1.  Late kidney dysfunction in a kidney transplant recipient.

Authors:  Michelle A Josephson
Journal:  Clin J Am Soc Nephrol       Date:  2013-12-26       Impact factor: 8.237

Review 2.  Rational clinical trial design for antibody mediated renal allograft injury.

Authors:  Shaifali Sandal; Martin S Zand
Journal:  Front Biosci (Landmark Ed)       Date:  2015-01-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.